1-Benzyl-4-methylpiperidin-3-ol

Catalog No.: 
ACNBAG469
CAS No.: 
384338-20-9
Molecular Formula: 
C13H19NO
Molecular Weight: 
205.30
1-Benzyl-4-methylpiperidin-3-ol structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$89.00InquiryInquiry
1g95%$240.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-Benzyl-4-methylpiperidin-3-ol
IUPAC Name1-benzyl-4-methylpiperidin-3-ol
MDL No.MFCD16619305
Molecular FormulaC13H19NO
Molecular Weight205.30
SMILESOC1CN(CC2=CC=CC=C2)CCC1C
InChI KeyQRGQXVUZVXXWAG-UHFFFAOYSA-N
Synonym1-benzyl-4-methylpiperidin-3-ol;4-Methyl-1-(phenylmethyl)-3-piperidinol;Trans-1-benzyl-4-methyl-piperidin-3-ol;3-Piperidinol, 4-Methyl-1-(phenylMethyl)-;1-benzyl-4-methylpiperidin -3-0l;1-benzyl-4-methyl-3-(methylamino)piperidin-4-ol
CAS No.384338-20-9
PubChem CID21955384

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACNBAG469 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACYJUQ467 route compound structure diagram
    ACYJUQ467955028-85-0In Stock
  4. Then
  5. ACNBAG469 route product structure diagram
    ACNBAG469384338-20-9
Inquiry

2. ACNBAG469 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACYJUQ467 route compound structure diagram
    ACYJUQ467955028-85-0In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACNBAG469 route product structure diagram
    ACNBAG469384338-20-9
Inquiry

3. ACNBAG469 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACNBAG469 route product structure diagram
    ACNBAG469384338-20-9
Inquiry

Comments (0)